[The investigation on the safety and immunogenicity of inactived hepatitis A vaccine AVAXIM].
OBJECTIVE
To investigate the safety and immunogenicity of AVAXIM in children and adults.


METHODS
One hundred and twenty-one children aged 6 - 12 years and 108 adults with negative HAV antibody, were inoculated by 0, 6 month procedure with inactivated HAV vaccine produced by Pasteur Merieux Connaught (AVAXIM 160 antigen unit).


RESULTS
The positive rates of anti-HAV IgG among children group and adult group were 98.15% and 94.17% respectively after one month of first inoculation, and became 100% and 97.22% after one month of second inoculation. The antibody positive rate was higher in children than in adults, but did not show statistical significance (P < 0.05). The side effects of AVAXIM inoculation were mild, mainly local pain with occurrences 1.7% - 2.8% in both groups. No serious systemic and local reactions were noticed.


CONCLUSIONS
AVAXIM had good safety and immunogenicity, seen not only in adults, but also in children.
Huang
G
G
Sanitation and Anti-epidemic Station of Wuzhou, Guangxi 543002, China.
Wan
Z
Z
Li
R
R
D000328:Adult; D002648:Child; D005260:Female; D006506:Hepatitis A / Q000517:prevention & control*; D035922:Hepatitis A Antibodies / Q000097:blood*; D022362:Hepatitis A Vaccines / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000276:immunology
D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D007074:Immunoglobulin G; D015164:Vaccines, Inactivated